BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, May 3, 2024
See today's BioWorld
Home
» No Buyout, but Acorda Banks $110M in Fampridine-SR Deal
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
No Buyout, but Acorda Banks $110M in Fampridine-SR Deal
July 2, 2009
By
Jennifer Boggs
No Comments
It wasn't the acquisition some investors had hoped for, but Acorda Therapeutics Inc. hardly could have asked for better terms in its ex-U.S. licensing deal for multiple sclerosis drug Fampridine-SR. (BioWorld Today)
BioWorld